Refractory Diffuse Large B-Cell Lymphoma Clinical Trials

14 recruiting

Refractory Diffuse Large B-Cell Lymphoma Trials at a Glance

24 actively recruiting trials for refractory diffuse large b-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Duarte, Columbus, and Sacramento. Lead sponsors running refractory diffuse large b-cell lymphoma studies include City of Hope Medical Center, Joseph Tuscano, and Mayo Clinic.

Browse refractory diffuse large b-cell lymphoma trials by phase

Treatments under study

About Refractory Diffuse Large B-Cell Lymphoma Clinical Trials

Looking for clinical trials for Refractory Diffuse Large B-Cell Lymphoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Diffuse Large B-Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Diffuse Large B-Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Phase 1

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 1

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+11 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
Phase 3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed240 enrolled41 locationsNCT07409428
Recruiting
Phase 2

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting
Phase 2

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center56 enrolled1 locationNCT07042438
Recruiting
Phase 1

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type+6 more
Lapo Alinari18 enrolled1 locationNCT05755087
Recruiting
Phase 1Phase 2

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Early Phase 1

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center9 enrolled1 locationNCT05800405
Recruiting
Phase 2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Phase 2

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD37 enrolled1 locationNCT05821088
Recruiting
Phase 2

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+8 more
University of Washington40 enrolled1 locationNCT05453396
Recruiting
Phase 2

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+9 more
City of Hope Medical Center36 enrolled1 locationNCT05672251
Recruiting
Phase 2

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRecurrent Nodal Marginal Zone LymphomaRefractory Diffuse Large B-Cell Lymphoma+11 more
Joseph Tuscano25 enrolled1 locationNCT06905509
Recruiting
Phase 2

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+1 more
Joseph Tuscano34 enrolled1 locationNCT06854159
Recruiting
Phase 3

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Recurrent and Refractory Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd390 enrolled1 locationNCT07011056